Architectural Oncology is not a network-centric model, a gene-network reinterpretation, a polypharmacology strategy, or an organelle-specific pathology framework.
Genes, pathways, and molecular interactions remain relevant, but they are no longer causally decisive when architectural feasibility becomes the binding constraint for persistence.
Interpretations that reduce architectural claims to additive target inhibition or signaling compensation fall outside the scope of this framework.
